Sintef Tto As

Oslo Universitetssykehus Hf

Einar Sulheim

Ruth Schmid

Heidi Johnsen

Per Martin Stenstad

Yrr Mørch

Yrr Morch

Kjersti Flatmark

Karianne Giller Fleten

Peter Molesworth

Described herein is a hydrophobic anti-cancer drug encapsulated into poly(alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.

Drug delivery system for treatment of cancer

The present invention provides a nanoparticle comprising a poly(alkyl cyanoacrylate) homopolymer, or copolymer, at least one active agent and an anionic and radical inhibitor, wherein the anionic and radical inhibitor is a compound having the following formula: wherein R1 is H; and R3, R4, R5, R6 and R7 are independently selected from the group consisting of —H, —OH, C1-C6 alkoxide, C1-C6 alkyl, halides, carboxylic acid, ketone or aldehyde; wherein the anionic and radical inhibitor is present in an amount of 0.001 to 15 wt %, as well as a process suitable for manufacture of the nanoparticle.

Nanoparticles

Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

PACA and cabazitaxel for anti-cancer treatment

The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Growing community of inventors

Trondheim, Norway

Einar Sulheim